Previous studies have demonstrated that plasma levels of palmitic acid (PA) have a strong association with Type-2 diabetes patients [39,40] and inhibit AKT, ERK, and eNOS activation as well as a VEGF-A-induced tube-like formation on Matrigel [41,42,43]. This evidence concerns the gene VEGFA and type 2 diabetes mellitus.